Recruitment Account Manager, UK
I am pleased to meet you!
II am Jens-Peter Lietz, Recruitment Account Manager at Syneos Health.
I am pleased to support you in the realisation of your career objectives.
We aim to create a maximum of transparency for you. This includes sharing also some high-level information about the therapeutic area and the concerning therapy options. Please note that this is not meant as a medical resource and should not be seen as any advise concerning AMD or any other therapeutic area.
If you feel that you are affected by AMD or witness any other eye related issues, please consult your ophthalmologist!
In a non-AMD affected eye, a picture is created by focusing light on the retina. The central point of vision is the so-called macula, where the highest concentration of photoreceptors (cones) is located. The macula, therefore, is the place where the central vision is created. Lateral the macula peripheral sight is created.
The so-called rods on the side of the macula are also responsible for detecting motion. Cones are creating a colourfull picture whilst rods are creating different shades of grey.
What is AMD?
Age-related Macular Degeneration (AMD) – the most common reason for blindness in the 50+ population worldwide (1)
There are two basic types of macular degeneration: “dry” and “wet.” Approximately 85% to 90% of the cases of macular degeneration are the “dry” (atrophic) type. “Dry” age-related macular degeneration does not involve any leakage of blood or serum.
Loss of vision may still occur. Patients with this “dry” form may have good central vision (20/40 or better) but substantial functional limitations, including fluctuating vision, difficulty reading because of their limited area of central vision, limited vision at night or under conditions of reduced illumination functional limitations, including fluctuating vision, difficulty reading because of their limited area of central vision, limited vision at night or under conditions of reduced illumination (2).
Adnan Tufail from the Moorfields Eye Hospital describes the pathogenesis of dry AMD by the following mechanism (2). The photoreceptors in the retina are producing waste (drusen) throughout the life. Over the time, the ability to digest this waste decreases which leads to a concentration of drusen can cause inflammation. As a result, the Bruch membrane and retinal pigment epithelium (RPE) cells degenerate and causes a slow loss of central vision.
In essence, dry AMD is therefore characterised as a progressive degeneration of the macula. It is defined by the following points:
– Drusen deposits >63 microns
– Pigmentary changes (hypo- or hyper-) of the RPE
– Atrophic macular degeneration (=geographic atrophy)
– Neovascular macular degeneration
For further information we recommend Adnan Tufail's presentation "‘Dry’ Age-related Macular
Degeneration (AMD)". Download.
The proposed solution
The solution is a special lens which creates an image of superior quality at each point of the retina and avoids the use of the AMD affected area of the macula. The product is placed in the capsular bag at routine cataract surgery. It is hydrophobic acrylic provided in a pre-loaded injector for insertion through a 2.2mm incision. Its Wide Angle design controls peripheral blur using unique patented multi-dimensional hyper-aspheric optics creating a continuum of focused images across 20 degrees of the retina without any noticeable compromise in MTF centrally.
A clinical trial with more than 100 patients provided the result that significant improvements in CDVA and CNVA post-implantation were recorded in patients with intermediate to advanced dry AMD far exceeding improvements achieved with antiVegF treatments (ETDRS gain of 7 letters) for wet AMD.
Evidence suggests that subjects with AMD implanted with standard monofocal IOLs during cataract surgery can expect a gain of 6.5 – 7.5 ETDRS letters (an ETDRS letter score can be calculated as follows: when 20 or more letters are read correctly at 4.0 m, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 m plus 30.(3)) compared with the approximate ETDRS letter gain of 15-24 letters in those implanted with the new IOL in this cohort from 8 surgeons in 4 European centres.
Click on the territory of your choice and you are directed to our online application form. You either can use your LinkedIn profile or upload your CV. Within two to three business days, our recruitment team will contact you to discuss further details. After you have been invited for a personal meeting, we will ask you to complete a short online questionnaire, helping us to fulfil your application successfully. Finally, you will meet out Project Director, Mr Steve Sanderson and receive an offer.
In the case of any further questions, please send us an email to firstname.lastname@example.org
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance.
10 Bloomsbury Way
Phone: +44 (0) 20 7632 1800